Panacea Biotec Ltd

{"description":"Panacea Biotech jumped after launching EU-funded DENSTAR, a 48-month project starting June 1, 2026 to advance its DengiAll dengue vaccine through Phase I/III studies in Africa and seek licensure.","url":"https://www.cnbctv18.com/market/panacea-biotech-share-price-sharp-surge-dengue-vaccine-candidate-dengiall-denstar-trigger-ws-l-19921991.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Hungary's health regulator revoked GMP certificates for Panacea Biotec's Baddi unit, which could significantly impact the company's operations and reputation in the pharmaceutical sector. This decision raises concerns about compliance and product quality.","url":"https://www.thehindu.com/business/hungarys-health-regulator-revokes-gmp-certificates-of-panacea-biotec-arms-baddi-unit/article70597017.ece","sentiment":"Negative","domain":"The Hindu"}

{"description":"Panacea Biotec has won a ₹315 crore order from UNICEF for bivalent oral polio vaccine (bOPV) supply from April 2026 to March 2030. This contract is expected to boost revenue and market position, with shares rising by 3.20% post-announcement.","url":"https://www.cnbctv18.com/market/stocks/panacea-biotec-share-price-wins-unicef-order-worth-rs-315-crore-for-bopv-supply-19701747.htm","sentiment":"Positive","domain":"CNBCTV18"}